Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Researchers want to see if a test for cancer DNA in the blood helps doctors decide whether to reduce Hodgkin lymphoma chemotherapy. The blood test is a circulating tumor DNA (ctDNA) test called Foresight CLARITY. ctDNA is genetic material released by tumor cells directly into the bloodstream.
Inotuzumab ozogamicin is a drug used to treat adults with B-cell acute lymphoblastic leukemia (ALL) that has come back or continued to grow despite prior therapy. In this study, researchers are evaluating its use in children and young adults with recurrent or persistent B-cell ALL.
Researchers want to see if giving stereotactic radiosurgery (SRS) after osimertinib is better than osimertinib alone for advanced lung cancer. The people in this study have non-small cell lung cancer (NSCLC) that metastasized (spread) to the brain. Their cancers have a mutation (change) in the EGFR gene, and they are taking or planning to take osimertinib.
Doctors are assessing a new photodynamic therapy (PDT) for prostate cancer that has not spread beyond the prostate. This treatment is performed in an operating room while you are under general anesthesia.
Ibrutinib and rituximab are the standard treatment for Waldenström's macroglobulinemia (WM) and lymphoplasmacytic lymphoma (LL). In this study, researchers want to see if giving the medication venetoclax with the standard treatment is safe and more effective than the standard treatment alone in people with previously untreated WM/LL.
Prostate cancers initially need the male hormone testosterone for growth. Hormone therapies that lower the level of testosterone are among the best treatments for prostate cancers that have metastasized (spread). The benefits of hormone treatments often do not last, however. Over time, many prostate cancers keep growing even with hormonal therapies. These are called castration-resistant prostate cancers (CRPC).
Breast cancer (TNBC) and non-small cell lung cancer (NSCLC) that spread to other parts of the body (metastasize) are usually treated with chemotherapy, immunotherapy, targeted therapies, and/or radiation therapy. In this study, researchers want to see if using stereotactic body radiosurgery (SBRT) to all metastatic tumors plus standard therapy is more effective than standard therapy alone in patients with oligometastatic TNBC or NSCLC (five or fewer metastatic tumors).
Researchers are assessing blinatumomab with dasatinib or imatinib and standard chemotherapy to treat leukemia. The people in this study have Philadelphia chromosome positive (Ph+) or ABL-class Philadelphia chromosome-like (Ph-like) B-cell acute lymphoblastic leukemia (B-ALL).
The purpose of this study is to assess stereotactic radiosurgery (SRS) to treat people with small cell lung cancer (SCLC) who have been newly diagnosed with brain metastases (cancer that spread to the brain). SRS specifically targets a very small area of the body. By targeting the part of the brain where the cancer has spread, SRS may shrink the cancer without damaging healthy brain tissue.
Researchers want to find the best dose of RYZ801 to give with RYZ811 in people with inoperable liver cancer. Inoperable means the cancer cannot be taken out with surgery. The people in this study have hepatocellular carcinoma (HCC) that makes high levels of a liver protein called GPC3.
